Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to B/F/TAF in Elderly HIV-1 Patients
NCT05243602Phase 4Completed
- Sponsor
- University of Nairobi
- Start
- Feb 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of Nairobi. Started Feb 2022; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05243602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243602.